| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Medicine, Banting and Best Diabetes Centre, The Toronto General Hospital, University of Toronto, Toronto, Canada M5G2C4
Glucagon-like peptides (GLPs) are secreted from enteroendocrine cells in the gastrointestinal tract. GLP-1 actions regulate blood glucose, whereas GLP-2 exerts trophic effects on intestinal mucosal epithelium. Although GLP-1 actions are preserved in diseases such as diabetes, GLP-2 action has not been extensively studied in the setting of intestinal disease. We have now evaluated the biological effects of a human GLP-2 analog in the setting of experimental murine nonsteroidal antiinflammatory drug-induced enteritis. Human (h)[Gly2]GLP-2 significantly improved survival whether administered before, concomitant with, or after indomethacin. h[Gly2]GLP-2-treated mice exhibited reduced histological evidence of disease activity, fewer intestinal ulcerations, and decreased myeloperoxidase activity in the small bowel (P < 0.05, h[Gly2]GLP-2- vs. saline-treated controls). h[Gly2]GLP-2 significantly reduced cytokine induction, bacteremia, and the percentage of positive splenic and hepatic bacterial cultures (P < 0.05). h[Gly2]GLP-2 enhanced epithelial proliferation (P < 0.05 for increased crypt cell proliferation in h[Gly2]GLP-2- vs. saline-treated mice after indomethacin) and reduced apoptosis in the crypt compartment (P < 0.02). These observations demonstrate that a human GLP-2 analog exerts multiple complementary actions that serve to preserve the integrity of the mucosal epithelium in experimental gastrointestinal injury in vivo.
glucagon-like peptide 1; peptide hormone; glucagon
This article has been cited by other articles:
|
|
 |
|
  D. L. Sigalet, L. E. Wallace, J. J. Holst, G. R. Martin, T. Kaji, H. Tanaka, and K. A. Sharkey Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2 Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G211 - G221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Anini, A. Izzo, G. Y. Oudit, P. H. Backx, and P. L. Brubaker Role of phosphatidylinositol-3 kinase-{gamma} in the actions of glucagon-like peptide-2 on the murine small intestine Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1599 - E1606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M Sinclair and D. J. Drucker Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential Physiology, October 1, 2005; 20(5): 357 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Martin, L. E. Wallace, B. Hartmann, J. J. Holst, L. Demchyshyn, K. Toney, and D. L. Sigalet Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome Am J Physiol Gastrointest Liver Physiol, March 1, 2005; 288(3): G431 - G438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Mayo, L. J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, and D. J. Drucker International Union of Pharmacology. XXXV. The Glucagon Receptor Family Pharmacol. Rev., March 1, 2003; 55(1): 167 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, T. Hansotia, B. Yusta, F. Ris, P. A. Halban, and D. J. Drucker Glucagon-like Peptide-1 Receptor Signaling Modulates beta Cell Apoptosis J. Biol. Chem., January 3, 2003; 278(1): 471 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Yusta, J. Estall, and D. J. Drucker Glucagon-like Peptide-2 Receptor Activation Engages Bad and Glycogen Synthase Kinase-3 in a Protein Kinase A-dependent Manner and Prevents Apoptosis following Inhibition of Phosphatidylinositol 3-Kinase J. Biol. Chem., July 5, 2002; 277(28): 24896 - 24906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D J Drucker Gut adaptation and the glucagon-like peptides Gut, March 1, 2002; 50(3): 428 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nian, J. Gu, D. M. Irwin, and D. J. Drucker Human glucagon gene promoter sequences regulating tissue-specific versus nutrient-regulated gene expression Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2002; 282(1): R173 - R183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Boushey, B. Yusta, and D. J. Drucker Glucagon-like Peptide (GLP)-2 Reduces Chemotherapy-associated Mortality and Enhances Cell Survival in Cells Expressing a Transfected GLP-2 Receptor Cancer Res., January 1, 2001; 61(2): 687 - 693. [Abstract] [Full Text]
|
|
|
|
|
|
D. G. Burrin, B. Stoll, R. Jiang, Y. Petersen, J. Elnif, R. K. Buddington, M. Schmidt, J. J. Holst, B. Hartmann, and P. T. Sangild GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis Am J Physiol Gastrointest Liver Physiol, December 1, 2000; 279(6): G1249 - G1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Yusta, R. P. Boushey, and D. J. Drucker The Glucagon-like Peptide-2 Receptor Mediates Direct Inhibition of Cellular Apoptosis via a cAMP-dependent Protein Kinase-independent Pathway J. Biol. Chem., November 3, 2000; 275(45): 35345 - 35352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lovshin, J. Estall, B. Yusta, T. J. Brown, and D. J. Drucker Glucagon-like Peptide (GLP)-2 Action in the Murine Central Nervous System Is Enhanced by Elimination of GLP-1 Receptor Signaling J. Biol. Chem., June 8, 2001; 276(24): 21489 - 21499. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
